企業プロフィール
Nutriband 株価・ニュース・カタリスト
- ティッカー:
- NTRB
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
7.36 USD (-2.13%)
終値
最終更新: 2026年10月1日
43.2M USD
時価総額
株価変動の要因
最新のモニタリング対象企業ニュースは「Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders」です。対応する終値の反応はまだ確認できません。
企業概要
Transdermal Pharmaceutical Company
Nutriband develops transdermal products and provides contract manufacturing services. Its strategy combines near-term manufacturing revenue with proprietary abuse-deterrent patch technology.
AVERSA Abuse-Deterrent Platform
AVERSA incorporates aversive agents into transdermal systems to discourage chewing, extraction, or other misuse. The platform is designed for potent drugs that benefit from continuous delivery but carry abuse risk.
AVERSA Fentanyl
The lead proprietary program applies AVERSA technology to a fentanyl patch. Nutriband is developing the product through the 505(b)(2) pathway with the goal of retaining analgesic delivery while adding abuse deterrence.
Contract Manufacturing Operations
Through Pocono Pharmaceutical, the company develops and manufactures topical and transdermal products for third parties. Services include formulation, coating, converting, packaging, and production of consumer and pharmaceutical patches.
Partner-Supported Development
Nutriband works with external manufacturers, development specialists, and regulatory advisers, including Kindeva for AVERSA Fentanyl. This model gives the company access to commercial-scale transdermal expertise without building every capability internally.
今後のカタリスト
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。